This test kit is designed for Research Use Only.
The calibrator and controls contain human source components, which have been tested and found non-reactive for hepatitis B surface antigen as well as HIV antibody with FDA licensed reagents. However, as there is no test method that can offer complete assurance that HIV, Hepatitis B virus or other infectious agents are absent, these reagents should be handled at the Biosafety Level 2, as recommended in the Centers for Disease Control/National Institutes of Health manual, "Biosafety in Microbiological and Biomedical Laboratories." 1984
Do not pipette by mouth. Do not smoke, eat, or drink in the areas in which specimens or kit reagents are handled.
The components in this kit are intended for use as an integral unit. The components of different lots should not be mixed.
It is recommended that standards and serum samples be run in duplicate.
Optimal results will be obtained by strict adherence to this protocol. Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from this may yield invalid data.
Glenn, J., Steinberg, W.M., Kurtzman, S.H., et at. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 level in patients before and after treatment of carcinoma of the pancreas. J. Clin. Oncol. 1988; 6:462-8.
Hayakawa, T., Kondo, T., Shibata, T. et al. Sensitive serum markers for detecting pancreatic cancer. Cancer 1988; 61:1827-31.
Koprowski, H., Herly, M., Steplewski, Z., et al. Specific antigen in serum of patients with colon carcinoma. Science 1981; 212:53-5
Malesci, A., Tommasini, M.A., Bonato, C. et al. Determination of CA19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenteroglogy 1987; 92:60-
Safi, F, Roscher, R., Bittner, R., et al. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas 1987; 2:398-403.
Steinberg, W. The clinical utility of CA 19-9 tumor associated antigen. American J. of Gastroenterology 1990; 85:350-355.
Steinberg, W.M., Gelfand, R., Anderson, K.K., et al. Comparison of the sensitivity and specificity of the CA 19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1986; 90:343-9.
Takasaki, H., Uchida, E., Tempero, M.A., et al. Correlative study on expression of CA 19-9 and DU-Pan-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res. 1988; 48:1435-8.
Tatsuta, M., Yamamura, H., Iishi H., et al. Values of CA19-9 in the serum, pure pancreatic juice and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor. Cancer 1985; 56:2669-73.
Wang, T.H. Lin, J.W., Chen, D.S., et al. Noninvasive diagnosis of advanced panceatic cancer by real-time ultrasonography, carcinoembryonic antigen, and carbohydrate antigen 19-9. Pancreas 1986; 1:219-23.
Strom BL, Maislin G, West SL, et al. Serum CEA and CA19-9: potential future diagnostic or screening tests for gallbladder cancer? Int. J. Cancer 1990; 45:821.